{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:55:26Z","timestamp":1769216126514,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bristol-Myers Squibb and Ono Pharmaceutical CO., LTD."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N\u2009=\u2009107) and ACPA-positive (N\u2009=\u2009446) groups. \u2018ACPA positive\u2019 was defined as\u2009\u2265\u200913.5\u00a0U\/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI\u2009\u2264\u200911) at 52\u00a0weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52\u00a0weeks. Drug retention rate at 52\u00a0weeks estimated by the Kaplan\u2013Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (\u0394mTSS\u2009\u2264\u20090.5) at 52\u00a0weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.<\/jats:p>","DOI":"10.1038\/s41598-020-76842-4","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T11:02:41Z","timestamp":1605178961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Daihei","family":"Kida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobunori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Fujibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hanabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Oguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yachiyo","family":"Kuwatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekata","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumori","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Nishiume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mochihito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Terabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"76842_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese, M. C. et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67, 547\u2013554 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1136\/ard.2010.139345","volume":"70","author":"JM Kremer","year":"2011","unstructured":"Kremer, J. M. et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis. 70, 1826\u20131830 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR3","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","volume":"71","author":"JE Gottenberg","year":"2012","unstructured":"Gottenberg, J. E. et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: Data from the \u2018Orencia and Rheumatoid Arthritis\u2019\u2019 registry\u2019. Ann. Rheum. Dis. 71, 1815\u20131819 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.170007","volume":"45","author":"LR Harrold","year":"2018","unstructured":"Harrold, L. R. et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: A US national observational study. J. Rheumatol. 45, 32\u201339 (2018).","journal-title":"J. Rheumatol."},{"key":"76842_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3109\/s10165-012-0760-4","volume":"23","author":"N Takahashi","year":"2013","unstructured":"Takahashi, N. et al. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod. Rheumatol. 23, 904\u2013912 (2013).","journal-title":"Mod. Rheumatol."},{"key":"76842_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3899\/jrheum.141288","volume":"42","author":"N Takahashi","year":"2015","unstructured":"Takahashi, N. et al. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: Effect of concomitant methotrexate after 24 weeks. J. Rheumatol. 42, 786\u2013793 (2015).","journal-title":"J. Rheumatol."},{"key":"76842_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/rheumatology\/keu418","volume":"54","author":"N Takahashi","year":"2015","unstructured":"Takahashi, N. et al. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: A retrospective observational study based on data from a Japanese multicentre registry study. Rheumatology (Oxford) 54, 854\u2013859 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"76842_CR8","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00296-015-3283-4","volume":"35","author":"N Takahashi","year":"2015","unstructured":"Takahashi, N. et al. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int. 35, 1707\u20131716 (2015).","journal-title":"Rheumatol Int."},{"key":"76842_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2474-15-14","volume":"15","author":"HG Nusslein","year":"2014","unstructured":"Nusslein, H. G. et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: A 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet. Disord. 15, 14 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"76842_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove, J. et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann. Rheum. Dis. 75, 709\u2013714 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff, M. et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from AMPLE trial. Ann. Rheum. Dis. 73, 86\u201394 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR12","doi-asserted-by":"publisher","unstructured":"Takeuchi, T. et al. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod. Rheumatol. https:\/\/doi.org\/10.1080\/14397595.2019.1703484 (2020).","DOI":"10.1080\/14397595.2019.1703484"},{"key":"76842_CR13","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1136\/annrheumdis-2014-205428","volume":"74","author":"C Hecht","year":"2015","unstructured":"Hecht, C. et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann. Rheum. Dis. 74, 2151\u20132156 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR14","doi-asserted-by":"publisher","first-page":"e0136611","DOI":"10.1371\/journal.pone.0136611","volume":"10","author":"Y Hamamoto","year":"2015","unstructured":"Hamamoto, Y. et al. Serological and progression differences of joint destruction in the wrist and the feet in rheumatoid arthritis\u2014A cross-sectional cohort study. PLoS ONE 10, e0136611 (2015).","journal-title":"PLoS ONE"},{"key":"76842_CR15","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1136\/annrheumdis-2014-206623","volume":"74","author":"HW van Steenbergen","year":"2015","unstructured":"van Steenbergen, H. W., Ajeganova, S., Forslind, K., Svensson, B. & van der Helm-van Mil, A. H. The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis. Ann. Rheum. Dis. 74, e3 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/s10165-011-0518-4","volume":"22","author":"T Kojima","year":"2012","unstructured":"Kojima, T. et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study. Mod. Rheumatol. 22, 339\u2013345 (2012).","journal-title":"Mod. Rheumatol."},{"key":"76842_CR17","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580\u20131588 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.11465","volume":"49","author":"Y Matsuda","year":"2003","unstructured":"Matsuda, Y. et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis. Rheum. 49, 784\u2013788 (2003).","journal-title":"Arthritis. Rheum."},{"key":"76842_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/s10165-010-0284-8","volume":"20","author":"H Nagasawa","year":"2010","unstructured":"Nagasawa, H., Kameda, H., Sekiguchi, N., Amano, K. & Takeuchi, T. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Mod. Rheumatol. 20, 337\u2013342 (2010).","journal-title":"Mod. Rheumatol."},{"key":"76842_CR20","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde, D. How to read radiographs according to the Sharp\/van der Heijde method. J. Rheumatol. 27, 261\u2013263 (2000).","journal-title":"J. Rheumatol."},{"key":"76842_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.33312","volume":"64","author":"V Foltz","year":"2012","unstructured":"Foltz, V. et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis. Rheum. 64, 67\u201376 (2012).","journal-title":"Arthritis. Rheum."},{"key":"76842_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0950-3579(96)80043-4","volume":"10","author":"DM van der Heijde","year":"1996","unstructured":"van der Heijde, D. M. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability. Baillieres. Clin. Rheumatol. 10, 435\u2013453 (1996).","journal-title":"Baillieres. Clin. Rheumatol."},{"key":"76842_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/art.10181","volume":"47","author":"D van der Heijde","year":"2002","unstructured":"van der Heijde, D. et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. Arthritis. Rheum. 47, 215\u2013218 (2002).","journal-title":"Arthritis. Rheum."},{"key":"76842_CR24","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1136\/rmdopen-2016-000345","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten, R. et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study. RMD Open 3, e000345 (2017).","journal-title":"RMD Open"},{"key":"76842_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg, J. E. et al. Brief report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: Results from the pan-European registry analysis. Arthritis. Rheumatol. 68, 1346\u20131352 (2016).","journal-title":"Arthritis. Rheumatol."},{"key":"76842_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"A Krishnamurthy","year":"2016","unstructured":"Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75, 721\u2013729 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer, A. et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann. Rheum. Dis. 73, 854\u2013860 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"76842_CR28","doi-asserted-by":"publisher","first-page":"e0175281","DOI":"10.1371\/journal.pone.0175281","volume":"12","author":"T Koga","year":"2017","unstructured":"Koga, T. et al. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. PLoS ONE 12, e0175281 (2017).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76842-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:50:43Z","timestamp":1670367043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76842-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["76842"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-76842-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.I. received grants, lecture fees, and fees for serving on speakers\u2019 bureaus from Daiichi Sankyo, Takeda Pharmaceutical, Hisamitsu Pharmaceutical, Otsuka Pharmaceutical, Taisho Toyama Pharmaceutical, Kaken Pharmaceutical, Eisai, Janssen Pharmaceutical, Bristol-Myers Squibb, Abbvie Japan, Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Astellas Pharma, and Pfizer Japan. T.K. received lecture fees (<\u2009US$5000) from Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, AbbVie, Bristol-Myers Squibb, and Pfizer, and $10000 from Chugai Pharma. N.T. received speaker\u2019s fees from Abbvie Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb (<\u2009$5000). Y.H. received speaker\u2019s fees from Abbvie Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb (<\u2009$5000). A.K. received lecture fees (<\u2009$5000) from Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, Chugai Pharma, Abbvie Japan, Bristol-Myers Squibb, UCB, Janssen, and Pfizer. All other authors have no conflicts of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19717"}}